Broadbent DM, Sampson CJ, Wang A, Howard L, Williams AE, Howlin SU, Appelbe D, Moitt T, Cheyne CP, Mobayen Rahni M, Kelly J, Collins J, García-Fiñana M, Stratton IM, James M, Harding SP for the ISDR Study Group.
Individualised screening for diabetic retinopathy: the ISDR study – rationale, design and methodology for a randomised controlled trial comparing annual and individualised risk-based variable-interval screening.
BMJ Open 2019 DOI: 10.1136/bmjopen-2018-025788
García-Fiñana M, Hughes DM, Cheyne CP, Broadbent DM, Wang A, Komárek A, Stratton IM, Mobayen-Rahni M, Alshukri A, Vora J, Harding SP.
Personalized risk-based screening for diabetic retinopathy: A multivariate approach versus the use of stratification rules.
Diabetes, Obesity and Metabolism 2018 DOI: 10.1111/dom.13552
Eleuteri A, Fisher AC, Broadbent DM, García-Fiñana M, Cheyne CP, Wang A, Stratton IM, Gabbay M, Seddon D, Harding SP for the ISDR Study Group.
Individualised variable interval risk-based screening for sight threatening diabetic retinopathy – the Liverpool Risk Calculation Engine.
Diabetologia 2017 DOI: 10.1007/s00125-017-4386-0
Sampson C, Tosh J, Cheyne C, Broadbent D, James M.
Health state utility values for diabetic retinopathy: protocol for a systematic review and meta-analysis.
Systematic Reviews 2015 DOI: 10.1186/s13643-015-0006-6
Conference presentations
Broadbent DM, Wang A, Cheyne CP, Lathe JG, Stratton IM, Vora J, García-Fiñana M, James M, Harding SP.
Individualised screening for diabetic retinopathy: the ISDR study – a randomised controlled trial of safety, efficacy and cost-effectiveness.
American Diabetes Association Conference, San Francisco,2019 DOI: 10.2337/db19-39-LB
Harding S, Sampson C, Criddle T, Broadbent D, James M.
The cost of screening for sight-threatening diabetic retinopathy.
Association for Research in Vision and Ophthalmology (ARVO), Vancouver, 2019.
Cheyne CP, Broadbent DM, Moitt T, Howard L, Howlin S, Silvera K, Appelbe D, Rahni MM, Stratton I, James M, Wang A, Williamson PR, Harding SP, García-Fiñana M.
Methodological aspects of the ISDR RCT: Investigating individualised variable interval screening for diabetic retinopathy in a screening population.
International Clinical Trials Methodology Conference, Brighton, 2019.
Sampson CJ, James M, Whynes D, Eleuteri A, Harding S.
Optimising risk-based screening: the case of diabetic eye disease.
Health Technology Assessment International Conference, Vancouver, 2018.
Byrne P, Broadbent DM, Thetford C, Gabbay M, Clark P, Wang A, Harding SP.
Putting patients’ eyes back into their bodies: implications of a social science study of screening and diabetes eye care.
European Association for the Study of Diabetes Eye Complications study group (EASDec), Belfast, 2018.
Wang A, Harding SP, Thetford C, Broadbent DM, Byrne P, Roberts J, ISDR PPI group.
Enabling patients to be partners in research – how to ensure publicly funded applied health services research is fit-for-purpose.
EASDec, Belfast, 2018.
Vazquez-Arango P, Wang A, Broadbent DM, Criddle T, Stratton IM, Vora JP, Harding SP.
Visual impairment in a population based evaluation of people with diabetes.
EASDec, Belfast, 2018.
Harding SP.
The UK as a clinical trials destination - 10 years of the National Institute for Health Research. Personalised medicine in the NHS.
NIHR Clinical Research Network Ophthalmology Symposium, ARVO, Baltimore, 2017.
Harding SP, Cheyne CP, Wang A, Broadbent DM, Vora JP, García-Fiñana M, Alshukri A, Mobayen-Rahni M, Fisher AC, Stratton IM.
Detecting sight threatening diabetic retinopathy in the 21st century – lessons from 20 years of screening in Liverpool.
Macula Society, Singapore, 2017.
Harding SP.
Personalising the interval in screening for sight threatening diabetic retinopathy.
Royal Society of Medicine, London, 2017
Appelbe D, Williamson P.
E-trials within the UKCRC CTU network – opportunities and challenges.
National Institute for Health Research e-trial Conference, 2017.
Sampson CJ, Tosh JC, Cheyne CP, Broadbent DM, Whynes DK, James M.
Systematic review and meta-analysis of health state utility values for diabetic retinopathy: implications for model-based economic evaluation.
Health Economists’ Study Group Conference, Birmingham, 2017.
Harding SP, Cheyne CP, Broadbent DM, Appelbe D, Wang A, Rahni M, Moitt T, Stratton IM, Szmyt D, Howlin S, Awoyale L, Williamson P, Vora JP, García-Fiñana M.
Safety of individualised variable interval screening for referable diabetic retinopathy – baseline data from the ISDR randomised controlled study.
EASDec, Budapest, 2017.
Harding S, Sampson S, Cheyne C, Broadbent D, Wang A, Mobayen-Rahni M, Alshukri A, Fisher A, Vora J, García-Fiñana M.
10 year observational study of patient related outcomes during expansion to full population coverage of a systematic diabetes eye care programme – the Liverpool Diabetic Eye Study.
ARVO, Seattle, 2016.
Thetford C, Byrne P, Gabbay M, Harding S, Broadbent D, Roberts J.
Comparing health professionals’ and patient perspectives of individualised screening intervals for diabetic retinopathy screening.
EASDec, Manchester, 2016.
James M, Sampson CJ, Van Eker D, Szmyt D, Harding SP.
Micro-costing diabetic eye screening: estimation of personal expense, attendance and health care resource use.
EASDec, Manchester, 2016.
Harding S, Sampson S, Cheyne C, Broadbent D,
Stratton I, Wang A, Garcia-Finana M
10 year observational study of patient related outcomes during expansion to full population coverage of a systematic diabetes eye care programme – the Liverpool Diabetic Eye Study,
EASDec, Manchester, 2016.
Sampson C, James M, Van Eker D, Szmyt D, Harding SP.
Health-related quality of life of people attending screening for diabetic retinopathy within a trial setting.
Manchester, 2016.
Wang A, Alshukri A, Rahni MM, Fisher AC, Broadbent DM, Appelbe D, Harding SP.
Building a dynamic functional clinical data warehouse (CDW) for personalised health care – lessons from the individualised screening for diabetic retinopathy (ISDR) study.
EASDec, Manchester, 2016.
Sampson C, James M, Whynes D.
Comparing health professionals’ and patient perspectives of individualised screening intervals for diabetic retinopathy screening.
EASDec, Manchester, 2016.
Thetford C, Byrne P, Gabbay M, Harding SP, Broadbent DM, Roberts J.
Individualised cost-effectiveness analysis in risk-based screening: practical and ethical?
Personalised Medicine and Resource Allocation Conference, Oxford, 2015.
Harding S, Eleuteri A, Broadbent D, Van der Hoek
M, Cheyne C, Wang A, Stratton I, Fisher A.
Individualised risk-based screening for sight
threatening diabetic retinopathy – the Liverpool
Risk Calculation Engine ARVO, Denver, 2015.
Byrne P, Thetford C, Gabbay M, Wang A, Broadbent D, Harding SP.
Patient perspectives of acceptability of risk-based individualized diabetic retinopathy.
EASDec, Turin, 2015.
Harding SP, Eleuteri A, Broadbent DM, Van der Hoek M, Cheyne CP, Stratton IM, Fisher AC.
Individualised risk-based screening for diabetic retinopathy: the Liverpool Risk Calculation Engine.
EASDec, Turin, 2015.
Sampson CJ, James M, Fisher AC and Harding SP,
Cost-effectiveness of a risk-based screening programme for diabetic retinopathy: a modelling approach
EASDec, Turin, 2015.
Broadbent DM, Harding SP, García-Fiñana M, Fisher AC, Bennett A, Appelbe DE, Wang A.
Introducing personalised risk based intervals in screening for diabetic retinopathy: the ISDR study.
EASDec, Turin, 2015.
Thetford C, Byrne P, Gabbay M, Harding S,
Roberts J (2014) Patient perspectives of
diabetic retinopathy screening and models of
diabetes care, Society for Academic Primary Care North Conference, Keele University, 2014.
